JNJ240705P148000
- 1.89
- -0.79-29.48%
Johnson & Johnson Newsroom
Unusual Options Activity: JNJ, CSCO and Others Attract Market Bets, JNJ V/OI Ratio Reaches 153.8
EST Jul 5th Morning Delivery - In the last two hours of trading, 9 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.Of
What's Going On With Johnson and Johnson Shares Friday?
Johnson and Johnson (NYSE:JNJ) shares are trending on Friday. In the last week, the pharmaceutical company announced positive results from two clinical trials and authorization from Health Canada for
J&J (JNJ) Trades Below 200 & 50-Day Moving Averages: Buy the Dip?
ohnson & Johnson’s (JNJ Quick QuoteJNJ - Free Report) stock has been trading below its 200-day and 50-day moving averages since the end of June. On Jul 3, the stock’s closing price of $145.69 was below its 50-day moving average of $147.61 and the 200-day moving average of 151.95.
Johnson & Johnson's bispecific antibody drug talquetamab has been approved for sale in South Korea.
On July 2, Johnson & Johnson's (JNJ.US) South Korea company announced that its bispecific antibody drug Talquetamab has been approved for launch in South Korea.
Johnson & Johnson Receives Canadian Approval for Rybrevant in First-line NSCLC
U.S. Indicated Dividend Payments Rose in Q2 Led by Alphabet's Initiation
Indicated dividend net changes for U.S. domestic common stocks rose $16.05B in Q2, as compared to a $16.03B increase in the prior quarter, according to the data from S&P Dow Jones Indices.
Top High Quality Stocks That Pay Dividends - UBS
Johnson & Johnson Lung Cancer Drug Gets Health Canada Approval
By Michael Susin Johnson & Johnson said the Canadian health authority issued a notice of compliance for its lung-cancer treatment, meaning the drug is authorized to be marketed under certain conditio
Express News | Health Canada Authorizes Rybrevant® (Amivantamab) in Combination With Carboplatin and Pemetrexed as the Only Targeted First-Line Treatment Approved for Patients With Non-Small Cell Lung Cancer With Egfr Exon 20 Insertion Mutations
Johnson & Johnson (JNJ.US) / Legend Biotech (LEGN.US) CAR-T therapy has achieved positive results in phase III.
According to the news from the Securities Times app, on July 3, Johnson & Johnson (JNJ.US) and Legend Biotech (LEGN.US) jointly announced the positive results of the planned second interim analysis of the Phase 3 CARTITUDE-4 study. The study evaluated the chimeric antigen receptor (CAR) T cell therapy Carvykti jointly developed by the two companies, compared to standard therapy, for the treatment of patients with relapsed or refractory multiple myeloma (MM) who are resistant to lenalidomide after 1st-line treatment. The interim analysis showed that compared with standard therapy, patients treated with Carvykti had a longer overall survival.
China International Capital Corporation: Colored contact lenses promote demand upgrade, and manufacturing business enters the golden development period.
Terminal demand upgrades, technological innovation, and changes in the market landscape will drive rapid development in the domestic industry chain. Contact lenses and colored contact lenses will usher in new development opportunities and are expected to continue to maintain a strong growth trend in the next few years.
Express News | Johnson & Johnson has received approval from the US Food and Drug Administration and the European Commission for SIRTURO (bedaquiline), a pharmaceutical.
Express News | Johnson & Johnson Receives Approval From U.S. FDA and European Commission for Sirturo® (Bedaquiline)
JNJ Should Rally Soon or See 3 Swings Higher at Least
Johnson & Johnson (JNJ) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average, and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue.
J&J Says Carvykti Beat Standard Drugs in Late-stage Blood Cancer Trial
Johnson & Johnson Says Interim Analysis of Blood Cancer Therapy Study Show Promise
Johnson & Johnson (JNJ) said on Tuesday interim analysis of the Phase 3 study of its experimental therapy, Carvykti, to treat certain patients with a type of blood cancer showed a statistically signif
Johnson & Johnson's Second Interim Analysis Of Phase 3 Cartitude-4 Study Of Carvykti Vs. Standard Therapies For Relapsed Or Lenalidomide-Refractory Multiple Myeloma, Show Statistically Significant, Clinically Meaningful Improvement In Overall Survival
Johnson & Johnson's Second Interim Analysis Of Phase 3 Cartitude-4 Study Of Carvykti Vs. Standard Therapies For Relapsed Or Lenalidomide-Refractory Multiple Myeloma, Show Statistically Significant, Cl
Express News | J&J -Safety Data Were Consistent With Approved Label
Express News | Carvykti® (Ciltacabtagene Autoleucel) Achieved Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Landmark Cartitude-4 Study
With 71% Ownership, Johnson & Johnson (NYSE:JNJ) Boasts of Strong Institutional Backing
Key Insights Significantly high institutional ownership implies Johnson & Johnson's stock price is sensitive to their trading actions 42% of the business is held by the top 25 shareholders Analys